Skip to main content

PAPEL DEL COLESTEROL EN LA ELIMINACION DE BETA-AMILOIDE (AB) COMO DIANA TERAPEUTICA EN LA ENFERMEDAD DE ALZHEIMER

SAF2013-47246-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion

  • Barbero-Camps, Elisabet
  • Roca-Agujetas, Vicente
  • Bartolessis, Isabel
  • Dios, Cristina de
  • Fernández-Checa, José C.
  • Marí, Montserrat
  • Morales, Albert
  • Hartmann, Tobias
  • Colell Riera, Anna
Macroautophagy/autophagy failure with the accumulation of autophagosomes is an early neuropathological feature of Alzheimer disease (AD) that directly affects amyloid beta (Ab) metabolism. Although loss of presenilin 1 function has been reported to impair lysosomal function and prevent autophagy flux, the detailed mechanism leading to autophagy dysfunction in AD remains to be elucidated. The resemblance between pathological hallmarks of AD and Niemann-Pick Type C disease, including endosome-lysosome abnormalities and impaired autophagy, suggests cholesterol accumulation as a common link. Using a mouse model of AD (APP-PSEN1-SREBF2 mice), expressing chimeric mousehuman amyloid precursor protein with the familial Alzheimer Swedish mutation (APP695swe) and mutant presenilin 1 (PSEN1-dE9), together with a dominant-positive, truncated and active form of SREBF2/SREBP2 (sterol regulatory element binding factor 2), we demonstrated that high brain cholesterol enhanced autophagosome formation, but disrupted its fusion with endosomal-lysosomal vesicles. The combination of these alterations resulted in impaired degradation of Ab and endogenous MAPT (microtubule associated protein tau), and stimulated autophagy-dependent Ab secretion. Exacerbated Ab-induced oxidative stress in APP-PSEN1-SREBF2 mice, due to cholesterol-mediated depletion of mitochondrial glutathione/mGSH, is critical for autophagy induction. In agreement, in vivo mitochondrial GSH recovery with GSH ethyl ester, inhibited autophagosome synthesis by preventing the oxidative inhibition of ATG4B deconjugation activity exerted by Ab. Moreover, cholesterol-enrichment within the endosomes-lysosomes modified the levels and membrane distribution of RAB7A and SNAP receptors (SNAREs), which affected its fusogenic ability. Accordingly, in vivo treatment with 2-hydroxypropyl-b-cyclodextrin completely rescued these alterations, making it a potential therapeutic tool for AD., This work was supported by Ministerio de Economía y Competitividad under Grant: SAF2013-47246-R to A.C., SAF2015-66515-R to A.M., SAF2015-69944-R to J.F-C.); FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea. “Una manera de hacer Europa”); Fundació La Marató de TV3 (2014-0930); Instituto de Salud Carlos III under Grant PI13/00374 and PI16/00930 to M.M., US NIAAA under Center grant P50- AA-11999 from Research Center for Liver and Pancreatic Diseases to J.F. C. We also want to thank the support of the AGAUR (2014-SGR785) and CERCA Programme from the Generalitat de Catalunya. C.dD. has a FPU fellowship from Ministerio de Economía y Competitividad. This work was developed (in part) at the Centre Esther Koplowitz., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Differential role of cathepsins S and B in hepatic APC-mediated NKT cell activation and cytokine secretion

  • Mingo, Álvaro de
  • Gregorio, Estefanía de
  • Chandra, Shilpi
  • Colell Riera, Anna
  • Morales, Albert
  • Kronenberg, Mitchell
  • Marí, Montserrat
Natural killer T (NKT) cells exhibit a specific tissue distribution, displaying the liver the highest NKT/conventional T cell ratio. Upon antigen stimulation, NKT cells secrete Th1 cytokines, including interferon γ (IFNγ), and Th2 cytokines, including IL-4 that recruit and activate other innate immune cells to exacerbate inflammatory responses in the liver. Cysteine cathepsins control hepatic inflammation by regulating κB-dependent gene expression. However, the contribution of cysteine cathepsins other than Cathepsin S to NKT cell activation has remained largely unexplored. Here we report that cysteine cathepsins, cathepsin B (CTSB) and cathepsin S (CTSS), regulate different aspects of NKT cell activation. Inhibition of CTSB or CTSS reduced hepatic NKT cell expansion in a mouse model after LPS challenge. By contrast, only CTSS inhibition reduced IFNγ and IL-4 secretion after in vivo α-GalCer administration. Accordingly, in vitro studies reveal that only CTSS was able to control α-GalCer-dependent loading in antigen-presenting cells (APCs), probably due to altered endolysosomal protein degradation. In summary, our study discloses the participation of cysteine cathepsins, CTSB and CTSS, in the activation of NKT cells in vivo and in vitro, This study was funded by grants from the Instituto de Salud Carlos III (PI16/00930 to MM), Ministerio de Economía y Competitividad (SAF2013-47246-R to AC, SAF2015-66515-R to AM) and co-funded by FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea. “Una manera de hacer Europa”); by NIH grant R37 71922 (to MK). Fundació Marató de TV3 (to AC), AGAUR and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

  • Tutusaus, Anna
  • Stefanovic, Milica
  • Boix, Loreto
  • Cucarull, Blanca
  • Blasco, Laura
  • García de Frutos, Pablo
  • Reig, Maria
  • Fernández-Checa, José C.
  • Marí, Montserrat
  • Colell Riera, Anna
  • Bruix, Jordi
  • Morales, Albert
Sorafenib, systemic treatment for advanced hepatocellular carcinoma (HCC), and regorafenib, novel second line treatment after sorafenib failure, have efficacy limited by evasive mechanisms of acquired-drug resistance. BCL-2 proteins participate in the response to tyrosine kinase inhibitors; however, their role in HCC therapy with sorafenib/regorafenib remains uncertain. BH3-mimetic ABT-263 (navitoclax) enhanced sorafenib activity, inducing cell death via a mitochondrial caspase-dependent mechanism, after BCL-xL/BCL-2 inhibition. Sorafenib-resistant hepatoma cells (HepG2R and Hep3BR) exhibited altered mRNA expression of BCL-2 and other anti-apoptotic family members, such as MCL-1, priming drug-resistant cancer cells to death by BH3-mimetics. ABT-263 restored sorafenib efficacy in sorafenib-resistant cell lines and HCC mouse models. Moreover, in mice xenografts from patient-derived BCLC9 cells, better tumor response to sorafenib was associated to higher changes in the BCL-2 mRNA pattern. HCC non-treated patients displayed altered BCL-2, MCL-1 and BCL-xL mRNA levels respect to adjacent non-tumoral biopsies and an increased BCL-2/MCL-1 ratio, predictive of navitoclax efficacy. Moreover, regorafenib administration also modified the BCL-2/MCL-1 ratio and navitoclax sensitized hepatoma cells to regorafenib by a mitochondrial caspase-dependent mechanism. In conclusion, sorafenib/regorafenib response is determined by BCL-2 proteins, while increased BCL-2/MCL-1 ratio in HCC sensitizes drug resistant-tumors against ABT-263 co-administration. Thus, changes in the BCL-2 profile, altered in HCC patients, could help to follow-up sorafenib efficacy, allowing patient selection for combined therapy with BH3-mimetics or early switch them to second line therapy., Study funded by grants from Instituto de Salud Carlos III (FIS PI15/00145 to M.R., FIS PI14/00962 to J.B., PI13/00374 and PI16/00930 to M.M., CIBEREHD and CIBERNED), Ministerio de Economía y Competitividad (SAF2015-69944-R to J.F.C., SAF2015- 66515-R to A.M. and P.G.F., and SAF2013-47246-R to A.C.) and co-funded by FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea); center grant P50- AA-11999 from Research Center for Liver and Pancreatic Diseases, US NIAAA to J.F.C.). Fundació Marató de TV3 (to A.C), AGAUR (2014_SGR_605 to J.B. and 2014_ SGR_785 to J.F.C.) and CERCA Programme / Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Oxidative inactivation of amyloid beta-degrading proteases by cholesterol-enhanced mitochondrial stress

  • Dios, Cristina de
  • Bartolessis, Isabel
  • Roca-Agujetas, Vicente
  • Barbero-Camps, Elisabet
  • Marí, Montserrat
  • Morales, Albert
  • Colell Riera, Anna
Familial early-onset forms of Alzheimer's disease (AD) are linked to overproduction of amyloid beta (Aβ) peptides, while decreased clearance of Aβ is the driving force leading to its toxic accumulation in late-onset (sporadic) AD. Oxidative modifications and defective function have been reported in Aβ-degrading proteases such as neprilysin (NEP) and insulin-degrading enzyme (IDE). However, the exact mechanisms that regulate the proteolytic clearance of Aβ and its deficits are largely unknown. We have previously showed that cellular cholesterol loading, by depleting the mitochondrial GSH (mGSH) content, stimulates Αβ-induced mitochondrial oxidative stress and promotes AD-like pathology in APP-PSEN1-SREBF2 mice. Here, using the same AD mouse model we examined whether cholesterol-enhanced mitochondrial oxidative stress affects NEP and IDE function. We found that brain extracts from APP-PSEN1-SREBF2 mice displayed increased presence of oxidatively modified forms of NEP and IDE, associated with impaired enzymatic activities. Both alterations were substantially recovered after an in vivo treatment with the cholesterol-lowering agent 2-hydroxypropyl-β-cyclodextrin. The recovery of the proteolytic activity after treatment was accompanied with a significant reduction of Aβ levels. Supporting these results, cholesterol-enriched SH-SY5Y cells were more sensitive to Aβ-induced impairment of IDE and NEP function in vitro. The rise of cellular cholesterol also stimulated the extracellular release of IDE by an unconventional autophagy-coordinated mechanism. Recovery of depleted pool of mGSH in these cells not only prevented the detrimental effect of Aβ on intracellular AβDPs activities but also had an impact on extracellular IDE levels and function, stimulating the extracellular Aβ degrading activity. Therefore, changes in brain cholesterol levels by modifying the mGSH content would play a key role in IDE and NEP-mediated proteolytic elimination of Aβ peptides and AD progression., This work was supported by the Ministerio de Economía y Competitividad, Spain [SAF2013-47246-R and RTI2018-095572-B-100 to A.C., SAF2015-66515-R to A.M.]; the FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea. “Una manera de hacer Europa”); the Fundació La Marató de TV3, Spain [2014-0930 to A.C.]; the Instituto de Salud Carlos III, Spain [PI16/00930 to M.M]; the Agencia de Gestió d’Ajuts Universitaris i de Recerca, Spain [2017_SGR_177]; and the CERCA Programme from the Generalitat de Catalunya, Spain. C.dD. has a FPU fellowship from Ministerio de Ciencia, Innovación y Universidades, Spain.